Donal CPA - Quantum BioPharma Chief Officer
| QNTM Stock | 3.84 0.17 4.24% |
Executive
Donal CPA is Chief Officer of Quantum BioPharma
| Age | 48 |
| Web | https://www.quantumbiopharma.com |
Quantum BioPharma Management Efficiency
The company has return on total asset (ROA) of (0.3612) % which means that it has lost $0.3612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6389) %, meaning that it created substantial loss on money invested by shareholders. Quantum BioPharma's management efficiency ratios could be used to measure how well Quantum BioPharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew MBA | Tarsus Pharmaceuticals | 47 | |
| Vincent Dequenne | Valneva SE ADR | 58 | |
| Yoshihisa Nagano | Tower Semiconductor | N/A | |
| MSc MD | Apogee Therapeutics, Common | N/A | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Peter Buhler | Valneva SE ADR | 54 | |
| Wendy AspdenCurran | Apogee Therapeutics, Common | N/A | |
| Dan Mulreany | Apogee Therapeutics, Common | N/A | |
| Timothy Moriarty | Teradyne | 63 | |
| Nachiappan Chidambaram | Lipocine | 56 | |
| Rafi Mor | Tower Semiconductor | 61 | |
| Hanneke Schuitemaker | Valneva SE ADR | N/A | |
| John Weaver | IPG Photonics | N/A | |
| Monica Forbes | Apogee Therapeutics, Common | 49 | |
| Guy Eristoff | Tower Semiconductor | 62 | |
| Dani Ashkenazi | Tower Semiconductor | 62 | |
| Dipal Patel | Valneva SE ADR | 50 | |
| Joshua Drumm | Valneva SE ADR | N/A | |
| Adrienne Kemp | Tarsus Pharmaceuticals | N/A | |
| Jane Henderson | Apogee Therapeutics, Common | 59 | |
| Ujjwal Kumar | Teradyne | N/A | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.36 |
Quantum BioPharma Leadership Team
Elected by the shareholders, the Quantum BioPharma's board of directors comprises two types of representatives: Quantum BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quantum. The board's role is to monitor Quantum BioPharma's management team and ensure that shareholders' interests are well served. Quantum BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quantum BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Cassidy, Vice QualityLucid | ||
| Donal CPA, Chief Officer | ||
| Zeeshan Saeed, CEO, Founder | ||
| Dr BPHARM, CEO Director | ||
| Jason Sawyer, Head Acquisitions | ||
| Maryann Adesso, Corporate Secretary | ||
| Nathan CPA, Chief Officer | ||
| Andrzej MD, Vice Lucid | ||
| Anthony Durkacz, Founder CoChairman | ||
| Randell Mack, President BioSciences |
Quantum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quantum BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 3.47 M | ||||
| Shares Outstanding | 1.55 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 1.54 % | ||||
| Number Of Shares Shorted | 15.23 K | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 91.86 X | ||||
| EBITDA | (10.06 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.